AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Dr Sanjeev Panchal, Country President and MD, AstraZeneca India, stated company's mission to bring innovative medicine faster ...

We recently compiled a list of 8 Cheap Growth Stocks to Buy According to Analysts. In this article, we will look at where ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

(Yicai) Sept. 30 -- AstraZeneca will strengthen its commitment to researching chronic and rare diseases in China, driving ...

Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...